MIMS Education

Better Together: Using Combination Therapy in the Intensive Lowering of LDL-C in Dyslipidemia

Better Together: Using Combination Therapy in the Intensive Lowering of LDL-C in Dyslipidemia

CardiologyInternal MedicineFamily MedicineGeneral Practice
A badge with ribbon in color black 1 point | An analog clock in color black 1 hour | A black calendar with white triangle in center that has a black exclamation point in the middle 12 Jun 2024 


About this course

The 2019 ESC guidelines governing the management of dyslipidemia recognizes the causal relationship between circulating low density lipoprotein cholesterol (LDL-C) levels, total duration of exposure to lipoproteins, and the size of a patient’s total atherosclerotic plaque burden. Given these, there is a need for patients at very high CV risk to reduce blood LDL-C levels early to as low as possible.

In line with the demanding target goals for lipid-lowering, the EAS 2021 practical guidelines call for the use of combination medications at the outset among the very high risk patients with high LDL-C unlikely to reach goals with statin therapy alone.

This module will review the most recent guidelines on lipid lowering therapy aimed at reducing cardiovascular morbidity. In particular, it will focus on the comprehensive discussion of combination therapy for dyslipidemia and how a clinician may maximize the use of these drugs to achieve treatment goals.

Learning outcomes

Upon completion of the educational activity, participants should be able to

  • Understand the role of LDL-C levels in the development of atherosclerotic cardiovascular disease (ASCVD)
  • Review the management of dyslipidemia beyond statin therapy

Topics covered

  • Factors contributing to plaque development in ASCVD, with emphasis on role of LDLs
  • Cardiovascular risk categories and LDL-C treatment goals
  • Lipid lowering treatment – statins, ezetimibe, PCSK9 inhibitors
  • Beyond statin therapy
    • Limitations of statins
    • Statin + Ezetimibe combination therapy
    • PCSK9 inhibitors
  • Treatment algorithms
    • ESC step-wise treatment algorithm for LDL-C
    • EAS algorithm for managing high LDL-C levels in ASCVD patients

Speaker for this course

Dr. Emily Tan

Senior Consultant Cardiologist & CMR Imaging Consultant,

Clinical Director of Women’s Health,

Cardiology Department, National Heart Institute Kuala Lumpur

Keywords: Dyslipidemia, Cardiovascular morbidity, Combination therapy for dyslipidemia